Immunotherapy has revolutionized cancer treatment by leveraging the body's own defenses. The molecular marker, mismatch repair deficiency (dMMR), plays a significant role in this process, with initial research suggesting it could predict the patient's immunotherapy response. However, recent findings have cast doubt on this, suggesting dMMR's role is more complex. Likewise, T-cell immunotherapy has transformed the treatment approach, offering an internally-sourced counter to the disease. Scientists have found a new way to enhance the ability of these T-cells to combat solid tumors, promising a new era of cancer therapies. This innovative research places T-cell immunotherapy at the vanguard of cancer treatment, intimating that our bodies hold the keys to the future of cancer therapy.
Full article here: https://medium.com/@lawsuithelpdesk/unraveling-the-enigma-mismatch-repair-deficiency-and-immunotherapy-response-immunotherapy-hailed-a66e20370bcb
